'Scrambler Therapy' Shows Benefit in Treatment of Chemotherapy-Induced Peripheral Neuropathy

Share this content:
(ChemotherapyAdvisor) – Scrambler therapy, a device that treats pain via noninvasive cutaneous electrostimulation, is beneficial for the treatment of chemotherapy-induced peripheral neuropathy (CIPN), according to results of a pilot study presented during the International Symposium on Supportive Care in Cancer, New York, NY, June 28-30, 2012.

CIPN, a common dose-limiting side effect of chemotherapy, has no known effective interventions.

Deirdre R. Pachman, MD, of the Mayo Clinic, Rochester, MN, and colleagues assessed the benefit of Scrambler therapy on 11 patients who had symptoms of CIPN for at least 1 month and tingling or pain rated as 4 on a scale of 10 during the prior week. Pain, tingling, and numbness were assessed at baseline and following Scrambler therapy, which was administered for up to 10 daily, 30-minute sessions. Symptoms of neuropathy were monitored daily during therapy using a numerical analogue scale questionnaire.

Percent change in mean pain was -48% and worst pain, -36%; reductions were also observed for mean tingling (-41%) and worst tingling (-43%) and for mean numbness (-21%) and worst numbness (-28%). She noted that persistent benefit out to 5 weeks was observed in some patients and no adverse events were reported.

“A prospective placebo-controlled clinical trial should be performed to confirm these preliminary findings,” Dr. Pachman concluded.

Abstract

 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs